Company overview
What does AtriCure, Inc. do?
AtriCure, Inc. (ATRC) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
What does AtriCure, Inc. do?
AtriCure, Inc. (ATRC) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
What industry is AtriCure, Inc. in?
Healthcare · Surgical & Medical Instruments & Apparatus
What was AtriCure, Inc.'s latest reported revenue?
$153.6M for Q2 2026, from 10-Q filed Jul 27, 2026.
What changed in the latest comparable period?
Revenue increased +12.8% ($136.1M to $153.6M; Q2 2025 vs Q2 2026).
Business model (from the public record)
Belvedere describes the business using the issuer’s SEC classification and the company description extracted from public filings. Segment mix, customer identity, and recurring-versus-transactional revenue are shown only when those facts are identified in the filing extract—not inferred.
Healthcare · Surgical & Medical Instruments & Apparatus · United States
Financial profile
- Revenue
- $153.6M 10-Q · Q2 2026 · Filed Jul 27, 2026
- Revenue growth YoY
- +12.8% Belvedere calculation · 10-Q · Q2 2026 · Filed Jul 27, 2026
- Gross margin
- +77.2% Belvedere calculation · 10-Q · Q2 2026 · Filed Jul 27, 2026
- Operating margin
- +6.3% Belvedere calculation · 10-Q · Q2 2026 · Filed Jul 27, 2026
- Net income
- $9M 10-Q · Q2 2026 · Filed Jul 27, 2026
- Operating cash flow
- — Not identified in latest matched XBRL period
- Capex
- — Not identified in latest matched XBRL period
- Belvedere FCF
- — Not identified in latest matched XBRL period
- FCF margin
- — Not identified in latest matched XBRL period
- Cash
- $167.8M 10-Q · Jun 30, 2026 · Filed Jul 27, 2026
- Debt
- $61M Belvedere calculation · 10-Q · Jun 30, 2026 · Filed Jul 27, 2026
- Net debt
- -$106.8M Belvedere calculation · 10-Q · Jun 30, 2026 · Filed Jul 27, 2026
- Shares
- 50,863,000 10-Q · Jun 30, 2026 · Filed Jul 27, 2026
Balance sheet snapshot
Cash $167.8M. Identified debt $61M. Net debt -$106.8M. Missing debt tags are not treated as a zero-debt capital structure.
Financial information is derived from public filings and other identified sources. Belvedere calculations may differ from company-defined non-GAAP measures. See methodology and source notes. Valuation multiples are omitted because a licensed market-data provider is not configured.
Latest filings
| Form | Filed | Period | Accession | Source |
|---|---|---|---|---|
| 4 | Sep 14, 2026 | Sep 11, 2026 | 0001653877-26-000006 | SEC |
| 4 | Sep 10, 2026 | Sep 8, 2026 | 0001336063-26-000008 | SEC |
| 4 | Sep 4, 2026 | Sep 2, 2026 | 0001336063-26-000006 | SEC |
| 4 | Aug 26, 2026 | Aug 24, 2026 | 0001861996-26-000006 | SEC |
| 4 | Aug 7, 2026 | Aug 5, 2026 | 0001566083-26-000006 | SEC |
| 4 | Aug 7, 2026 | Aug 5, 2026 | 0001796057-26-000010 | SEC |
| 4 | Aug 3, 2026 | Jul 30, 2026 | 0001230584-26-000008 | SEC |
| 4 | Jul 30, 2026 | Jul 28, 2026 | 0001862458-26-000011 | SEC |
| 4 | Jul 30, 2026 | Jul 28, 2026 | 0001205069-26-000005 | SEC |
| 4 | Jul 30, 2026 | Jul 29, 2026 | 0001666600-26-000004 | SEC |
| 10-Q | Jul 27, 2026 | Jun 30, 2026 | 0001323885-26-000035 | SEC |
| 8-K | Jul 23, 2026 | Jul 23, 2026 | 0001323885-26-000032 | SEC |
| 4 | Jul 2, 2026 | Jun 30, 2026 | 0001230584-26-000006 | SEC |
| 4 | Jul 2, 2026 | Jun 30, 2026 | 0001862458-26-000008 | SEC |
| 4 | Jul 2, 2026 | Jun 30, 2026 | 0001861996-26-000004 | SEC |
| 4 | Jul 2, 2026 | Jun 30, 2026 | 0001565823-26-000006 | SEC |
| 4 | Jul 2, 2026 | Jun 30, 2026 | 0001336063-26-000004 | SEC |
| 4 | May 22, 2026 | May 20, 2026 | 0001566083-26-000004 | SEC |
What changed
Each line is an arithmetic comparison of sourced facts. It is not a thesis.
Research view
Belvedere has not published an initiation or update on AtriCure, Inc.. Universe inclusion is not a rating, a forecast, or coverage in the sell-side sense.
Research Radar
| Kind | Change | Explanation | Source | Date |
|---|---|---|---|---|
| Revenue | +12.8% | Revenue increased +12.8% ($136.1M to $153.6M; Q2 2025 vs Q2 2026). | 10-Q · RevenueFromContractWithCustomerExcludingAssessedTax | Jul 27, 2026 |
| Revenue acceleration | -1.4 pp | Quarterly revenue YoY growth moved from +14.3% to +12.8% (-1.4 percentage points). | 10-Q · BelvedereRevenueGrowthYoY | Jul 27, 2026 |
| Margin change | $0.772 | Reported gross margin was +77.2% in the latest comparable period. | 10-Q · BelvedereGrossMargin | Jul 27, 2026 |
| Cash | $167.8M | Cash and cash equivalents were $167.8M as of the latest reported balance-sheet date. | 10-Q · CashAndCashEquivalentsAtCarryingValue | Jul 27, 2026 |
| Share count | $50.9M | Shares outstanding were 50,863,000 as of the latest reported date. | 10-Q · CommonStockSharesOutstanding | Jul 27, 2026 |
Rankings
- Fastest-Growing Companies in the Belvedere Universe · rank 45 · +12.8%
- Strongest Balance Sheets · rank 34 · +15.8%
- Belvedere Undercoverage Screen · rank 8 · 44
- Healthcare Companies by Revenue Growth · rank 2 · +12.8%
Industry context
AtriCure, Inc. is mapped to Healthcare (Surgical & Medical Instruments & Apparatus) from SIC metadata on the SEC submission. Mapping is a classification convenience, not a claim that every peer is economically comparable.
Belvedere Research Profile
This measures researchable information characteristics. It is not investment advice, a credit rating, or a buy/sell/hold recommendation.
Presence of core income-statement, cash-flow and balance-sheet concepts in SEC XBRL.
Comparable-period revenue history and operating-result availability.
Availability of margin, cash-flow and per-share concepts used in screening.
SEC periodic reports, current reports, proxy statement and website identified in submissions.
Distinct filing years in the current archive window plus comparable prior-period revenue.
Risks
Belvedere does not manufacture generic risk language. Material risks are those the issuer discloses in its periodic reports, particularly Item 1A of the latest Form 10-K.
A Form 10-K was not present in the current filing window.
Sources
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Jul 27, 2026
- Accession
- 0001323885-26-000035
- Concept
- RevenueFromContractWithCustomerExcludingAssessedTax
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Jul 27, 2026
- Accession
- 0001323885-26-000035
- Concept
- BelvedereRevenueGrowthYoY
(RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30 / RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30) - 1
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Jun 30, 2026
- Filed
- Jul 27, 2026
- Accession
- 0001323885-26-000035
- Concept
- CashAndCashEquivalentsAtCarryingValue
Disclosure
Belvedere Research publishes informational analysis. Nothing on this site is investment advice, an offer, or a solicitation to buy or sell any security.
This page is a company intelligence / data profile. It is not a research report unless a dated note is attached above. Rankings appearing here are independent of any issuer compensation.
Frequently asked questions
- What does AtriCure, Inc. do?
- AtriCure, Inc. (ATRC) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
- What industry is AtriCure, Inc. in?
- AtriCure, Inc. is classified in Healthcare (Surgical & Medical Instruments & Apparatus).
- When did AtriCure, Inc. last file a periodic report?
- AtriCure, Inc. last filed a 10-Q on Jul 27, 2026 (accession 0001323885-26-000035).
- What was AtriCure, Inc.'s latest revenue?
- $153.6M for Q2 2026, sourced from 10-Q filed Jul 27, 2026.
- Does Belvedere cover AtriCure, Inc.?
- AtriCure, Inc. is in the Belvedere universe. Presence in the universe is not the same as active initiation coverage.